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Abstract
Background: T1 mapping using modified Look-Locker inversion recovery (MOLLI) provides quantitative information
on myocardial tissue composition. T1 results differ between sites due to variations in hardware and software
equipment, limiting the comparability of results. The aim was to test if Z-scores can be used to compare the results
of MOLLI T1 mapping from different cardiovascular magnetic resonance (CMR) platforms.
Methods: First, healthy subjects (n = 15) underwent 11 combinations of native short-axis T1 mapping (four CMR
systems from two manufacturers at 1.5 T and 3 T, three MOLLI schemes). Mean and standard deviation (SD) of
septal myocardial T1 were derived for each combination. T1 maps were transformed into Z-score maps based on
mean and SD values using a prototype post-processing module. Second, Z-score mapping was applied to a
validation sample of patients with cardiac amyloidosis at 1.5 T (n = 25) or 3 T (n = 13).
Results: In conventional T1 analysis, results were confounded by variations in field strength, MOLLI scheme, and
manufacturer-specific system characteristics. Z-score-based analysis yielded consistent results without significant
differences between any two of the combinations in part 1 of the study. In the validation sample, Z-score mapping
differentiated between patients with cardiac amyloidosis and healthy subjects with the same diagnostic accuracy as
standard T1 analysis regardless of field strength.
Conclusions: T1 analysis based on Z-score mapping provides consistent results without significant differences due
to field strengths, CMR systems, or MOLLI variants, and detects cardiac amyloidosis with the same diagnostic
accuracy as conventional T1 analysis. Z-score mapping provides a means to compare native T1 results acquired
with MOLLI across different CMR platforms.
Keywords: Myocardial disease, Tissue analysis, Magnetic resonance imaging, T1 mapping, Standardization, Z-
score, Amyloidosis
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Background
The ability to extract a multitude of information from soft
tissues in a non-invasive manner has allowed cardiovascu-
lar magnetic resonance (CMR) to become the preferred
imaging modality for tissue characterization in many or-
gans. With late gadolinium enhancement (LGE) [1] and
T2-weighted short tau inversion recovery (STIR) [2] im-
aging, dedicated variants of conventional CMR techniques
were introduced to cardiac applications to detect regional
myocardial lesions and edema, respectively, establishing
CMR as an essential diagnostic tool in myocardial diseases.
By design these techniques are optimized to generate max-
imum contrast between normal and abnormal areas of
the myocardium to facilitate qualitative (visual) assess-
ment. The introduction of single-breathhold pulse se-
quences for cardiac T1 mapping such as MOLLI [3]
for clinical CMR systems has added an additional layer
of information, as they enable a direct quantitative as-
sessment of both focal or global signal intensities in
clinical routine. T1 mapping allows for evaluating
myocardial tissue properties by deriving absolute
values of the magnetic tissue property T1 from a spe-
cific region or the entire myocardium, which then can
be compared to local reference values derived from
healthy controls. Thus, T1 mapping intrinsically car-
ries the potential to also detect diffuse myocardial dis-
orders. A multitude of studies have proven the validity
of this concept for various myocardial diseases and
conditions including cardiac amyloidosis [4], Fabry’s
disease [5], myocarditis [6], and diffuse myocardial fi-
brosis [7]. The Heart Failure Association of the Euro-
pean Society of Cardiology recently identified
parametric mapping as one of six areas of innovative
imaging methods with the potential to revolutionize
the assessment of heart failure [8].
Various pulse sequence schemes have been developed
for clinical T1 mapping [9–11]. Depending on their tech-
nical approach, their accuracy and precision vary, resulting
in significantly different reference ranges for myocardial
T1 [12]. Moreover, results are confounded by external fac-
tors such as field strength and manufacturer-specific hard-
ware design of the CMR system. Therefore it has been
recommended that each site should generate their
own local reference ranges from site-specific T1 mea-
surements of healthy controls or of patients without
other signs or history of myocardial disease [13, 14].
However, this approach does not solve the problem
of results not being directly comparable from differ-
ent sites or CMR systems. Moreover, the lack of a
uniform reference range is perceived as a barrier for
the translation of findings from studies that were
performed with other acquisition schemes, and thus
seriously limits further development and clinical dis-
semination of T1 mapping.
In biostatistics, Z-scores are multiples of standard de-
viations (SD) from the mean of a normally distributed
population [15]. In clinical medicine they are typically
used to compare a quantitative test result to non-intuitive
reference data, e.g. for gender-, age- and size-specific di-
mensions of the aortic root in children [16]. The aim of
our study was to apply Z-scoring to T1 mapping in order
to standardize reporting of results. We hypothesized that
the use of Z-scores would result in universal T1 results
that are comparable and clinically meaningful irrespective
of the mapping variant, CMR system, and field strength
used.
Methods
The study consisted of two parts. First (evaluation step),
Z-score mapping was applied to T1 maps obtained from
healthy subjects (as confirmed by normal findings on elec-
trocardiogram (ECG), transthoracic echocardiography,
and cardiopulmonary exercise test; n = 15) in order to
evaluate the variability of results in normal controls. All
participants underwent T1 mapping with 2 to 3 different
MOLLI schemes on four CMR systems from two different
manufacturers at three sites (11 T1 maps for each subject).
Second, a validation step was performed. Z-score mapping
was applied to T1 maps from patients with cardiac trans-
thyrein (ATTR) amyloidosis (as confirmed by endomyo-
cardial biopsy and/or bone marrow scintigraphy) who
underwent T1 mapping with one MOLLI scheme at 1.5 T
(n = 25) or 3 T (n = 13) at a fourth site using normal data
from healthy subjects who were scanned on the same 1.5
T system (n = 14) or 3 T system (n = 16) at the same site
with the same MOLLI scheme.
Image acquisition – evaluation step
Fifteen healthy subjects (25 ± 4 years; 7 male) under-
went multiple T1 mapping CMR studies in mid-cavity
short axis orientation at three sites within 1 week. In
order to achieve reproducible positioning of the im-
aging planes, the “systolic 3-of-5” approach was used
[17]. At site 1, T1 mapping was performed on a 1.5 T
CMR system (Achieva, software release 5.1.8; Philips
Healthcare, Best, The Netherlands) and on a 3 T (Inge-
nia, software release 5.1.8, Philips Healthcare) system
using MOLLI 3b (3b) 3b (3b) 5b, MOLLI 5b (3b) 3b,
and MOLLI 5 s (3 s) 3 s. At site 2, T1 maps were ac-
quired on a 1.5 T Siemens Avanto (software release
D13B; Siemens Healthineers, Erlangen, Germany) sys-
tem using the same 3 MOLLI variants. At site 3,
MOLLI 3b (3b) 3b (3b) 5b and MOLLI 5b (3b) 3b were
obtained similar to sites 1 and 2 from a 3 T (Skyra,
software release E11, Siemens Healthineers); MOLLI 5
s (3 s) 3 s was not available on this system. Only prod-
uct mapping packages were used for MOLLI T1 map-
ping. Scanning was performed at each site by one local
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operator with >5 years and > 2000 scans of CMR ex-
perience using a standardized approach for short-axis
slice positioning [17].
Common imaging parameters for T1 mapping in-
cluded slice thickness 8 mm, field-of-view 360 mm, echo
time 1.07–1.22 ms, repetition time 2.14–2.44 ms, flip
angle 20° for 3 T Philips Ingenia or 35° for the other
systems).
For the assessment of global left ventricular (LV) pa-
rameters, standard breath-hold balanced stead-state
free-precession (bSSFP) images were acquired in 2-
chamber and 4-chamber long-axis views.
Image acquisition – validation step
A second set of healthy subjects and patients with cardiac
amyloidosis (ATTR, diagnosed by comprehensive workup
including right-ventricular endomyocardial biopsy and/or
DPD scintigraphy) underwent MOLLI 5 s(3 s)3 s either on
a 1.5 T (Ingenia, Philips Healthcare; healthy subjects: 7
male, 7 female; 53 ± 7 years; cardiac amyloidosis patients:
16 male, 9 female; 66 ± 10 years) or a 3 T (Ingenia, Philips
Healthcare; healthy subjects: 11 male, 5 female; 54 ± 3 years;
cardiac amyloidosis patients: all 13 male; 68 ± 12 years).
Common CMR imaging parameters included slice thick-
ness 10mm, field-of-view 300mm, echo time 1.17ms,
repetition time 2.34ms, flip angle 35° at 1.5 T or 20° at 3 T.
For the assessment of global LV parameters, standard
breath-hold bSSFP images were acquired in short-axis
stacks.
Z-score mapping
Image analysis was performed using a research version of
cvi42 (Circle Cardiovascular Imaging Inc., Calgary, Canada)
equipped with a prototype Z-score mapping module.
For Z-score mapping, average values of septal LV myo-
cardial T1 were derived from the T1 maps generated by
the CMR systems of all healthy control subjects and
patients with cardiac amyloidosis by manual delineation of
endocardial and epicardial contours with a standard
segmentation tool. The software was set to automatically
exclude the outer 20% of subendocardial and subepicardial
layers in order to minimize partial volume effects from
adjacent blood pool or extra-myocardial tissues as recom-
mended [14]. Based on the results, mean and SD were
calculated separately for each MOLLI variant and each
group of subjects on each system.
In a second step, Z-score maps were generated for each
T1 map from healthy subjects (evaluation step) and cardiac
amyloidosis patients (validation step) based on the mean
and SD values derived from corresponding T1 maps of the
healthy subjects using the prototype Z-score module. Es-
sentially, the Z-score module calculates the Z-score by
Z-score ¼ ðT1-meanÞ=SD
for each pixel of a T1 map, where T1 is the observed
pixel value on the T1 map, and mean and SD are the
mean and standard deviation of native myocardial T1
obtained from a group of healthy subjects with the given
MOLLI variant and CMR system.
From the results, a Z-score map is generated where the
intensity of each pixel corresponds to the Z-score of the T1
value of the corresponding pixel on the T1 map. As pixel
intensities on DICOM images must have integer values, Z-
score values are multiplied by 100 for visualization and
storage (for example, a Z-score of 1.5 would be presented
as 150). The Z-score map is shown and stored using a di-
verging colour scheme [18] (see Additional file 1) that was
generated using Colorbrewer 2.0 (http://colorbrewer2.org;
Cynthia Brewer, Mark Harrower and The Pennsylvania
State University).
Finally, average Z-scores of septal LV myocardial T1
were derived from all Z-score maps by copying the
endocardial and epicardial contours from the T1 maps
using the same standard segmentation tool as described
above. Average Z-scores were noted for each map, and
mean and SD of Z-scores were calculated for each
MOLLI variant for healthy subjects and for cardiac
amyloidosis patients as described above for T1.
Global LV parameters (end-diastolic volume, ejection
fraction, mass) were assessed from the cine images using
biplane long-axis (evaluation step) or multi-slice short-
axis (validation step) analysis.
Statistical analysis
A normal distribution of the results was verified for each
group of results using the Shapiro-Wilk Test and the
Kolmogorov-Smirnov Test. In the evaluation step,
ANOVA was used to test for the presence of significant
differences. This was done separately for the native T1
results from 1.5 T and 3 T. If Levene’s test did not show
homogeneity of variance, Welch’s ANOVA was per-
formed. Afterwards a Bonferoni post-hoc analysis was
performed to conduct multiple comparisons.
Independent t-tests were used to make comparisons
between the two field strength using the same MOLLI
from the same vendor.
In the validation step, independent t-tests were used to
make comparisons in-between the two groups of healthy
subjects and in-between the two cardiac amyloidosis
patient groups as well as between healthy subjects and
cardiac amyloidosis patients at corresponding field
strengths. In case of significant differences, a power ana-
lysis was performed using the software program G*Power
(Version 3.1) in order to estimate the statistical power of
the results. If results were non-significant, an equivalence
test (two one sided t-tests, TOST) was performed in the
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statistics software RStudio (Version 1.2.1335, 2009–2019
RStudio, Inc., Boston, Massachusetts, USA).
For the assessment of sensitivity and specificity, ranges
of normal were defined as.
mean−2SDð Þ to meanþ 2SDð Þ
from the healthy subject data. Besides power analysis
and equivalence tests, all statistical analysis was per-
formed using SPSS (version 24, Statistical Package for
the Social Sciences (SSPS), International Business Ma-
chines, Inc., Armonk, New York, USA).
Results
Evaluation step
Table 1 provides global LV parameters of the healthy
subjects as derived from cine CMR images. Figure 1
shows the results of cardiac T1 mapping in healthy sub-
jects at different sites with different CMR systems, field
strengths, and MOLLI schemes (for tabular data see
Additional file 1) including results of Bonferroni post-
hoc analysis. Both Shapiro-Wilk tests and Kolmogorov-
Smirnov tests were performed and confirmed normal
distribution of all T1 results in the healthy subjects. As
expected, there were significant differences between
mean native myocardial T1 values derived from different
field strengths, manufacturers, and MOLLI schemes
using both the classic ANOVA for 1.5 T and the Welch’s
ANOVA for 3 T (p < 0.001, respectively). Independent t-
tests showed significant differences between 1.5 T and 3
T for all comparisons made (always p < 0,001). While
most SDs amounted to < 5% of mean T1 (≤33 ms at 1.5
T and ≤ 58ms at 3 T), SD of MOLLI 3–3-5b data from
the Philips system at 3 T was 97ms (8.5% of mean T1),
without any identifiable technical reason for the high
variance of T1 values acquired with this specific combin-
ation. Figure 2 presents the corresponding Z-score
values for the healthy subjects. As expected (proving the
validity of the approach), mean Z-scores of healthy sub-
jects were at or closely to 0.0 and ranged within − 2.71
to + 2.17.
In contrast to the T1 results, there was no significant
difference detectable between the Z-scores derived from
different field strengths, manufacturers, and MOLLI
schemes using ANOVA (p = 1.0). A typical set of Z-score
maps from one healthy subject is presented in Fig. 3.
Validation step
As for the evaluation step, Table 1 provides global LV
parameters as derived from cine CMR for both healthy
subjects and cardiac amyloidosis patients. The results for
T1 and Z-score analyses from healthy subjects and car-
diac amyloidosis patients are presented in Figs. 4 and 5,
respectively. As expected, patients with amyloidosis ex-
hibited significantly higher myocardial T1 values than
healthy subjects at the same field strength (p < 0.001,
power 1.0). Native T1 was also different between 1.5 T
and 3 T in both healthy subjects and cardiac amyloidosis
patients (p < 0.001, power 1.0). Based on Z-score map-
ping using a threshold of Z = 2, amyloidosis was detected
with the same sensitivity (96% at 1.5 T, 100% at 3 T, re-
spectively) and specificity (100% at both 1.5 T and 3 T,
respectively) as with T1 mapping, and the difference be-
tween healthy subjects and cardiac amyloidosis patients
remained significant at both field strengths (p < 0.001
with a power of 1.0, respectively). In contrast no signifi-
cant difference was observed for healthy subjects (p =
0.985) or patients with cardiac amyloidosis (p = 0.552)
between results from 1.5 T or 3 T. For Z-scores from
healthy subjects at different field strength, TOST verified
equivalence at epsilon = 0.75 (p = 0.03, 95% TOST inter-
val − 0.62 to 0.63). For cardiac amyloidosis patients from
different field strength, TOST did not show equivalence
at the same epsilon level of 0.75 (p = 0.309, 95% TOST
interval − 0.69 to - 1.53) but at epsilon = 1.6 (epsilon =
magnitude of region of similarity). Figure 6 shows exam-
ples of Z-score maps of cardiac amyloidosis patients at
1.5 T and 3 T.
Discussion
Our results indicate that Z-score mapping might over-
come the limitations of T1 mapping that are related to
confounding effects of CMR hardware and software. The
use of Z-score mapping should be further explored as a
Table 1 Essential characteristics and global left ventricular (LV) parameters derived from cardiovascular magnetic resonance (CMR)
cine images in the evaluation step (healthy subjects) and validation step (healthy subjects and cardiac amyloidosis patients). Age
and LV parameters are given as mean ± standard deviation. EDV = end-diastolic volume; EF = ejection fraction
Subjects Field strength N Age (years) Male/ female LV EDV (ml) LV mass (g) LV EF (%)
Evaluation Healthy 1.5 T & 3 T 15 24 ± 4 7 / 8 187 ± 23.7 87 ± 20.9 62 ± 3.7
Validation Healthy 1.5 T 14 53 ± 7 7 / 7 161 ± 18.3 81 ± 15.2 60 ± 3.6
Healthy 3 T 16 54 ± 3 11 / 5 170 ± 29.8 91 ± 24.1 62 ± 2.7
Amyloidosis 1.5 T 25 66 ± 10 16 / 9 179 ± 35.4 178 ± 53 50 ± 11.2
Amyloidosis 3 T 13 68 ± 12 13 / 0 165 ± 32.6 167 ± 40 52 ± 13.7
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Fig. 1 Native myocardial T1 (mean ± 2SD indicating 2.3rd/ 97.7th percentile) and results of Bonferroni post-hoc analysis in healthy subjects at
different sites with different CMR systems, field strengths, and MOLLI schemes (for tabular data see Additional file 1).
* = p < 0.05, ns = non-significant
Fig. 2 Z-score values of native T1 from healthy subjects (n = 15) at different sites with different CMR systems, field strengths, and MOLLI schemes
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standardization tool for quantitative mapping of native
relaxation times in the myocardium.
In cardiac applications, changes of myocardial tissue
composition lead to changes of myocardial T1, which
can be detected by established T1 mapping methodology
with high reproducibility. Yet, due to the complexities of
the hardware and software components involved, abso-
lute numbers of normal and abnormal T1 differ between
CMR systems and imaging centers, limiting the inter-
changeability of results. In this study we tested whether
the transformation of native T1 values into Z-scores
based on prior knowledge of normal ranges generated
with a given combination of hardware/ software could
eliminate site-specific differences of results.
In conventional T1 mapping, confounding effects of
field strength, system design, and pulse sequence scheme
are minimized post-hoc by interpreting the results in the
light of local reference values. In Z-score mapping, this
step is integrated into the image processing in order to
make the results directly comparable between cohorts of
different reference ranges. In the evaluation part of this
study, Z-score mapping was applied as an additional
post-processing step to a variety of MOLLI T1 data sets
(native T1 maps) that were acquired with different hard-
ware/ software combinations in a group of healthy sub-
jects. While conventional analysis of the T1 maps
showed the expected differences in myocardial T1 based
on field strength and MOLLI scheme [12], analysis of Z-
score maps yielded homogenous results without signifi-
cant differences between the different sources. In the
validation part of the study, Z-score mapping was ap-
plied to MOLLI T1 data sets from healthy subjects and
cardiac amyloidosis patients acquired at 1.5 T or at 3 T
in order to assess the diagnostic accuracy of Z-score
mapping for differentiating normal from abnormal T1
behavior. Analysis of Z-score maps differentiated cardiac
Fig. 3 Full set of Z-score maps from a 22-year-old healthy female with corresponding Z-scores of native septal myocardium and diverging
colour scale
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amyloidosis from normal myocardium with the same
sensitivity and specificity as conventional T1 analysis.
However, while the spectrum of T1 results depended
largely on field strength, results of Z-score maps showed
no significant differences between patients studied at
1.5 T vs. 3 T, or between healthy subjects studied at 1.5
T vs. 3 T. Thus, Z-score mapping allowed for directly
comparing results of T1 measurements across different
hardware/ software combinations including different
field strengths.
The variation of T1 results is reflected by the SD of the
mean for a group of measurements, and has been used as a
marker for the reproducibility of T1 measurements within
groups of healthy subjects [19]. Based on this parameter,
there were some differences in diagnostic performance be-
tween different hardware/ software combinations in the
evaluation part of this study. While SDs ranged from 24 to
33ms at 1.5 T and from 44 to 58ms in four combinations
at 3 T, the SD of one particular combination at 3 T
amounted to 97ms. While it could be expected that the 3–
Fig. 4 Native myocardial T1 of healthy subjects at 1.5 T (n = 14) or 3 T (n = 16) and cardiac amyloidosis patients at 1.5 T (n = 25) or 3 T (n = 13).
Acquisition scheme: MOLLI 5(3)3b, * = p < 0.05
Fig. 5 Z-score values of native T1 from healthy subjects at 1.5 T (n = 14) or 3 T (n = 16) and cardiac amyloidosis patients at 1.5 T (n = 25) or 3 T
(n = 13). * = p < 0.05, ns = non-significant
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3-5 MOLLI scheme performed worse than 5–3 schemes at
3 T due to insufficient recovery times (in relation to myocar-
dial T1 at 3 T) between subsequent inversion experiments,
it remains unclear why this was the case on one 3 T CMR
system but not on the other that were used. We could not
identify any external confounders such as differences in
heart rate of the healthy subjects during the different acqui-
sitions. This phenomenon allowed us to study the impact of
variations in the performance of the underlying acquisition
strategies on Z-score results. If a site records a large SD of
native T1 when generating normal data for its T1 measure-
ments, this translates into a wide normal range. When this
normal range is then applied in clinical routine, very high or
very low T1 results will be required to qualify as “abnormal”
at this site. In other words, T1 measurements will have a
lower sensitivity for detecting disease at this site as com-
pared to T1 measurements from sites with lower SD within
control measurements. In Z-score mapping, the high SD of
the specific 3–3-5 variant at 3 T resulted in a shift of the Z-
scores and the corresponding color zones, visualizing the
reduced discriminatory power of this variant. Thus, differ-
ences in sensitivity of a T1 mapping acquisition scheme are
passed-on to Z-score maps, or in other words: Z-score map-
ping does not enhance the diagnostic performance of a T1
mapping acquisition strategy. At the same time, the obvious
effects of the normal range on the diagnostic value of both
standard T1 mapping and Z-score mapping underline the
importance of operating with optimized acquisition schemes
and with normal values that are carefully generated and
valid for a specific site.
From a clinical perspective, Z-score results have to be
interpreted in the light of the given clinical question. As
they represent biological continuous data, there is no
per-se cut-off value between “normal” and “disease”, and
no predefined maximum value. Instead, ranges of Z-
scores have to be established for different disease entities,
and there will be overlap between Z-scores between dis-
eases with mild effects on T1 and normal, corresponding to
the underlying T1 behavior. Z-score mapping has the
potential to enhance the ability of T1 mapping to detect
subtle changes in these “low-magnitude pathologies” [14]
by allowing for generating patient-specific Z-score maps
based on granular age- and gender-specific databases of
normal T1 in an automated fashion. Future studies will be
necessary to generate such databases (e.g. from population-
based studies of healthy subjects) and implement auto-
mated Z-score mapping. However, rigorous standardization
of analysis procedures is necessary in order to avoid magni-
fication of small differences by applying Z-scores from low-
variation normal data (e.g. large septal mid-cavity regions of
interest (ROIs)) to situations of higher variation (e.g. small
ROIs) or from other mean levels (e.g. apical orientation).
As does T1 mapping, Z-score mapping allows for both
ROI-based numerical analysis and colour-based visual
assessment. In order to facilitate visual detection of ab-
normal myocardial tissue, a diverging colour scale was
Fig. 6 Examples of Z-score maps and corresponding T1 maps from two cardiac amyloidosis patients and one healthy subject. Left: 66-year-old
male patient at 1.5 T,.mid: 78-year-old male patient at 3 T, right: 22-year-old healthy female at 1.5 T
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implemented in the Z-score mapping module rather
than a rainbow color scale [18]. The current recommen-
dations for clinical applications of T1 mapping demand
that “look up tables are set according to site-specific
ranges of normal” in order to be applied for T1 maps
[14]. Since the use of specific ranges of normal for a
given hardware/ software combination is at the center of
Z-score mapping, the Z-score approach inherently ful-
fills this requirement, and the proposed color scheme
might be usable without further adjustments when ap-
plied to other data sets with their respective mean and
SD values.
In our study, only variants of MOLLI were available
for comparison. In principle, Z-score mapping should
equally be applicable to T1 data from other acquisition
methods including shortened MOLLI (ShMOLLI) [9],
saturation recovery single-shot acquisition (SASHA)
[10], saturation pulse prepared heart rate independent
inversion recovery (SAPPHIRE) [11], and others, pro-
vided that the normal behavior (mean, SD) of that
method is known. Based on the results of the evaluation
part of this study, similar effects would be expected
when applying Z-score mapping to data from any of
those acquisition methods as for going from one MOLLI
scheme to another, i.e. homogenization of the levels of
the results while maintaining sensitivity and specificity
of the respective technique [12, 20]. Furthermore, the
general considerations discussed above on behavior,
comparability, and analysis of T1 mapping data apply
equally to data from T2 mapping. Thus, Z-score map-
ping might also be useful for standardizing the analysis
of T2 maps from different sources [21, 22]. However,
this was not investigated in this project and requires fur-
ther studies.
Another potential way of standardizing results from T1
mapping involves the use of standardized phantoms. In this
approach, phantoms with predefined, stable T1 values [23]
might be scanned with a site-specific T1 mapping variant.
The results could then be standardized using linear or non-
linear correction algorithms to reach either the “true” T1 of
the phantom as provided by the manufacturer, or an agreed-
upon “standard” T1 (e.g. 1000ms for phantoms whose T1
values correspond to those of normal myocardium). In con-
trast to the phantom approach, Z-score mapping does not
require additional (and costly) hardware, and standardizes in
relation to the actual biological tissue of interest rather than
an external body. On the other hand, phantom measure-
ments are able to detect systematic changes of magnetic sys-
tem behavior over time (“drift”), which might be missed by
Z-score mapping (and conventional T1 mapping) unless
normal ranges are verified or reassessed on a regular basis.
Thus, regular phantom measurements remain an important
tool for quality control [24] even if Z-score mapping is used
instead of standard T1 analysis.
For this study, a condition with large-magnitude bio-
logical changes (cardiac amyloidosis) was chosen to test the
performance of Z-score mapping as compared to standard
T1 analysis. While the results of our study demonstrated
no loss of diagnostic accuracy with the use of Z-score
analysis, further studies are necessary to assess the perform-
ance of this approach in small-magnitude biological
changes (e.g. diffuse myocardial fibrosis). In order to
enhance diagnostic accuracy in these scenarios, large multi-
dimensional normal databases might be used to generate
maps of age- and sex-matched Z-scores for individual pa-
tients. As another limitation of our study, Z-score mapping
was not tested in low-T1 myocardial diseases (i.e. Fabry’s,
iron overload). Even if its diagnostic behavior should not
differ in these situations from high-T1 diseases, future stud-
ies in cohorts of such patients are warranted to verify the
validity of the Z-score approach in these scenarios.
Conclusions
In summary, the use of Z-score mapping for quantifying
native myocardial T1 provided consistent results without
significant differences between data from different field
strengths, CMR systems, or MOLLI variants in healthy
subjects. Z-score mapping identified patients with cardiac
amyloidosis with the same diagnostic accuracy as conven-
tional T1 analysis. Z-score mapping holds the potential to
allow for standardized quantification and reporting of na-
tive myocardial T1 across different CMR hardware/ soft-
ware combinations, and for comparing MOLLI T1 results
from different CMR systems and centers in both research
and clinical routine.
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